Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBITDA Margin (2020 - 2026)

Cytek Biosciences filings provide 6 years of EBITDA Margin readings, the most recent being 68.64% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 8527.0% to 68.64% in Q4 2025 year-over-year; TTM through Dec 2025 was 31.92%, a 2956.0% decrease, with the full-year FY2025 number at 31.92%, down 2956.0% from a year prior.
  • EBITDA Margin hit 68.64% in Q4 2025 for Cytek Biosciences, down from 8.83% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 16.63% in Q4 2024 to a low of 68.64% in Q4 2025.
  • Median EBITDA Margin over the past 5 years was 4.47% (2022), compared with a mean of 7.14%.
  • Biggest five-year swings in EBITDA Margin: soared 1548bps in 2024 and later tumbled -8527bps in 2025.
  • Cytek Biosciences' EBITDA Margin stood at 1.52% in 2021, then soared by 585bps to 7.35% in 2022, then soared by 36bps to 9.97% in 2023, then soared by 67bps to 16.63% in 2024, then crashed by -513bps to 68.64% in 2025.
  • The last three reported values for EBITDA Margin were 68.64% (Q4 2025), 8.83% (Q3 2025), and 10.99% (Q2 2025) per Business Quant data.